Genitourinary Cancers | Specialty

Second-Line Cabozantinib in mRCC

March 26th 2015

Second-Line Treatments in RCC

March 26th 2015

Investigational Approaches in RCC

March 26th 2015

VEGF Versus mTOR in Non-Clear Cell RCC

March 26th 2015

Sunitinib Versus Pazopanib in Renal Cell Carcinoma

March 26th 2015

Managing Untreated Metastatic Renal Cell Carcinoma

March 26th 2015

Role of Radiation Therapy in Renal Cell Carcinoma

March 26th 2015

Introduction: Surgical Approaches in mRCC

March 26th 2015

Refining Approaches to Reach Treatment Goals in mRCC

March 26th 2015

Patricia Hofstra on Alternatives to Acquisition in Healthcare

March 25th 2015

Patricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.

Studies of Second-Line Immunotherapies in Bladder Cancer Hold Promise

March 16th 2015

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.

PD-1 Pathway Combos Lead the Way in RCC Immunotherapy

March 16th 2015

The prospects for combining anti–PD-1 pathway agents with other checkpoint blockade inhibitors or with agents that target angiogenesis are among the most promising immunotherapy approaches under development for patients with metastatic renal cell carcinoma.

Task Force PSA Recommendation Needs Updating, LUGPA President Says

March 16th 2015

A United States Preventive Services Task Force recommendation against the use of prostate specific antigen testing needs to be updated, said Gary Kirsh, MD, president of the Large Urology Group Practice Association.

Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder Cancer

March 14th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.

Dr. Voss on Early Efficacy Signals in DART Study for Advanced Kidney Cancer

March 12th 2015

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses early efficacy signals in the phase I/II DART study.

Dr. Haas on Adjuvant Sorafenib or Sunitinib for RCC

March 2nd 2015

Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).

Targeted-Chemo Combination Active In Sarcomatoid, High-Risk RCC

March 2nd 2015

A fourth of patients with sarcomatoid or poor-risk metastatic renal-cell carcinoma responded to treatment with the combination of sunitinib and gemcitabine.

Adding Anti-PD-L1 Antibody to Bevacizumab Induces Responses in mRCC

March 2nd 2015

An investigational antibody that targets programmed death-ligand 1 (PD-L1) in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with metastatic renal cell carcinoma (mRCC) in an open-label phase Ib study.

Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC

February 26th 2015

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

Dr. McKay on Statin Use in Patients With mRCC

February 26th 2015

Rana R. McKay, MD, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.